ALK and cholangiocarcinoma: Initiation of clinical trials with ceritinib in CCA patients, irrespective of their ALK mutation status, with retrospective analysis on the clinical responses, is warranted to fully unlock ceritinib’s therapeutic potential in cholangiocarcinoma.